Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Colonic Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Rectal Neoplasms 1 Polycystic Ovary Syndrome 1 Neuroendocrine Tumors 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphangioleiomyomatosis 1 Liver Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Chemoprevention 1 Carcinoma, Hepatocellular 1

Interventions

Rituximab 301 Cyclophosphamide 241 Peripheral Blood Stem Cell Transplantation 115 fludarabine phosphate 111 Filgrastim 93 Etoposide 85 Radiotherapy 81 Lenalidomide 81 Vincristine 79 Prednisone 79 Mycophenolic Acid 67 Doxorubicin 62 Whole-Body Irradiation 59 Cyclosporine 59 Bendamustine Hydrochloride 59 Melphalan 57 Tacrolimus 54 Busulfan 52 obinutuzumab 50 fludarabine 50 Cytarabine 49 Methotrexate 45 Antilymphocyte Serum 43 Bortezomib 42 Methylprednisolone 37 Carmustine 37 sargramostim 36 ibritumomab tiuxetan 33 ibrutinib 30 Dexamethasone 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Follicular × Resveratrol × Clear all

NCT00455416 2008-05-21

KLYMF

Oslo University Hospital

Phase 2 Unknown

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡